Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.

Competing Interests: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Jun GongHonoraria: Amgen, Astellas Pharma, Clinical Congress Consultants Consulting or Advisory Role: Amgen, Astellas Pharma, Clinical Congress ConsultantsSandip PatelConsulting or Advisory Role: Eli Lilly, Novartis, Bristol-Myers Squibb, AstraZeneca/MedImmune, Nektar, Compugen, Illumina Speakers' Bureau: Merck, Boehringer Ingelheim Research Funding: Bristol-Myers Squibb (Inst), Pfizer (Inst), Roche (Inst), Amgen (Inst), AstraZeneca/MedImmune (Inst), Fate (Inst), Merck (Inst)David FrishbergStock and Other Ownership Interests: Amgen (I) Consulting or Advisory Role: Ultragenyx (I), Replimmune (I) Travel, Accommodations, Expenses: Ultragenyx (I), Replimmune (I)Veronica R. Placencio-HickokPatents, Royalties, Other Intellectual Property: Patent 17814046.3-1111 PCT/US2017037558. Sensitization of tumors to therapies through endoglin antagonism (Inst)Richard TuliConsulting or Advisory Role: AstraZeneca Research Funding: AstraZeneca, AbbVie Patents, Royalties, Other Intellectual Property: Patent pending: Methods of Treating Gastrointestinal Malignancies, Application No. 16/256,840 filed: January 24, 2019, inventor (Inst)Young K. ChaeConsulting or Advisory Role: Foundation Medicine, Boehringer Ingelheim, Biodesix, Counsyl, AstraZeneca, Guardant Health, Takeda, Roche, Immuneoncia, Hanmi, Eli Lilly, Tempus Speakers' Bureau: Roche, Merck, AstraZeneca, Eli Lilly Research Funding: AbbVie, Bristol-Myers Squibb, Lexent Bio, Freenome, Biodesix Travel, Accommodations, Expenses: HanmiRazelle KurzrockLeadership: CureMatch, CureMetrix Stock and Other Ownership Interests: CureMatch, IDbyDNA, Soluventis Honoraria: Roche, EUSA Pharma, NeoGenomics Laboratories, Biocom, NeoMed Therapeutics, Advanced Therapeutics, LEK, AACR, Chugai Pharma USA, Wiley Consulting or Advisory Role: Actuate Therapeutics, Loxo, XBiotech, Neo-Med, Roche, Gaido, Soluventis, Pfizer, Merck Speakers' Bureau: Roche Research Funding: Guardant Health (Inst), Sequenom (Inst), Merck Serono (Inst), Genentech (Inst), Pfizer (Inst), Foundation Medicine (Inst), Incyte (Inst), Konica Minolta (Inst), Grifols (Inst), OmniSeq (Inst), Debiopharm Group (Inst), Boehringer Ingelheim (Inst) Travel, Accommodations, Expenses: Roche, EUSA Pharma, NeoGenomics Laboratories, Biocom, NeoMed Therapeutics, Advanced Therapeutics, LEK, AACR, Chugai Pharma USA, WileyAndrew E. HendifarConsulting or Advisory Role: Novartis, Ipsen, Perthera, Celgene, AbbVie Research Funding: Ipsen Travel, Accommodations, Expenses: Halozyme No other potential conflicts of interest were reported.